Skip to main content

Warning Letter Against Lantech For Violating FDA Rules

Warning Letter Against Lantech For Violating FDA Rules

Warning Letter Against Lantech For Violating FDA Rules

Introduction

On August 8, 2019, The Food and Drug Administration of U.S. issued a warning letter to Hyderabad-based Lantech Pharmaceuticals Limited after finding that the company failed to investigate complaints related to the blood pressure medicine Valsartan.

In December 2018, Lantech Pharmaceuticals was notified by their customer firm that the solvent recovered by the company contained the potential mutagenic impurities, N-Nitrosodiethylamine (NDEA) which resulted in cancer. A year after, concerns related to cancer-causing impurities found in samples of Valsartan were raised in the US.

The letter stated that the company failed to investigate and resolve complaints raised by its customer firm that used its contract solvent recovery services to make the valsartan active pharmaceutical ingredient (API). This included their failure in investigating the solvent that contained N-Nitrosodimethylamine (NDMA), a cancer-causing impurity found in samples collected from equipment used by the company to recover the solvents. The company acted as a solvent recovery facility for other companies that manufacture API used in Valsartan, a generic version of Diovan.

Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!